ID: MRFR/HC/7659-HCR | June 2021 | Region: Global | pages
The cell line development market is expected to cross USD 10,700 million in 2027 at a CAGR of ~12.5% during the forecast period. Cell line development (CLD) is a process that is being used for a variety of research and drug development and production application such as drug target identification and biologic drug production. The process begins by selecting host cells; the most commonly used host cells are Chinese Hamster Ovary (CHO)or HEK293 cells. The cell line development market growth can be attributed to the growing vaccine production globally, the developing biotechnology sector, and the rising demand for monoclonal antibodies. However, there are pitfalls in the cell line development market, such as complex regulatory scenarios and stem cell research issues.
The rising prevalence of COVID-19 is projected to influence cell line development market growth over the forecast period. As the coronavirus outbreak continues, the majority ofthe pharmaceutical companies experienced a significant loss, thereby hampering the cell line development market.The COVID-19 pandemic has highly affected the economy across the globe; this severely impacts the production process and demand across numerous verticals and disrupts the supply chain.
Many companies halted their manufacturing and supply operations in the initial phase of the pandemic. However, the current situation of COVID-19 is expected to reach normalcy since the medical professionals and health authorities in the countries are taking the necessary steps to fight against the virus. Furthermore, pharmaceutical companies and research institutions worldwide are high have shifted their research activities in finding vaccine for COVID-19, thereby putting the development of other therapeutics on hold.
Increasing R&D and introduction of new technologies for cell line development
Rise in vaccine productionby using cell line development process
High capital investment and complexity associated with the cell development process
The cell line development process is initiated via organs or tissues collected from mammalians or non-mammalian sources. The source for this process is a prerequisite for the development of stable cell lines for commercial purposes. Therefore, the rising adoption of mammalian sourcesfor the production of monoclonal antibodies and the increasing demand for expressing complex proteins similar to human beings are anticipated to provide significant growth opportunities.
In addition, the improved quality cell engineering and expression systems for the development of this source are projected to fuel the cell line development market demand. There areapproximately 4,000 mammalian cell linesthat are available for use in biologics production and research. This factor is also likely to serve the mammalian source segment with lucrative opportunities.
Value Chain Analysis
Raw materials are the primary input in the cell line development market and are the basic elements of the end-product. The raw material used in cell line development can be classified as high-tech and low-tech materials. For instance, cell culture media used in cell line development are low-tech materials that include inorganic elements and components such as salts, calcium, basic mineral elements, etc. High-tech raw materials used in the manufacturing of cell culture media include materials such asserum, animal components, growth factors, etc., which are generally derived from donor patients. Thus, the first step in raw material management is segmenting the raw materials according to theirscarcity, cost, and its potential impact on the manufacturing process.
The suppliers supply the raw material to the manufacturing company, which is processed, molded, and shaped by the manufacturers for the manufacturing of the cell line. Supplier management is thus crucial for high-value and performance-dependent sectors.
In this process, the product strategies are ready, and the manufacturing process of the product starts. The manufacturing process begins with the assembling of raw materials. The sourcing of raw materials is the initial phase in the manufacturing of the devices. Raw materials that are required are base media components, growth matrix components, additives, promoters, and markers. The cost of this process can be reduced by finding substitutes for the raw material. Manufacturing is a fast process, which is followed by the testing of the products.
The distributor is in charge of delivering the product to the client who initially had ordered the product, whose main goal remains the same to distribute the product on time in its original condition.
The cell line development industry needs to partner and collaborate with market players such as large hospitals and even distributors of medical supplies
The customer is the organization that demands the product and sells it; this is likewise the part in the supply chain where the role of a supply chain regularly reaches an end. The cell line development manufacturers need to form a collaboration with large clients, industries, and hospitals. Collaboration between manufacturers and large players also favors market penetration as most consumers are not knowledgeable about the right cell culture media products suitable for their needs.
The consumer is the end user that purchases the product and uses it. Pharmacy and biotech companies, laboratories are the people that finally implement the product. Thus, the goal is to increase the value for the consumer, which has led to the extension of the supply chain to include final consumers and even post-market reverse logistics. There is an urgent need to leverage social media for generating product awareness and brand attraction. Real-time demand sensing by engaging consumers directly will trump forecast-based supply chain models.
The primary cell line is expected to be the fastest-growing segment in 2020 dueto its various application in cell morphology, genetics, and cell metabolism. In the process of cell development, cells are extracted from normal, embryonic, and malignant tissues. These cells are propagated in vitro.
Hybridoma or (Chinese Hamster Ovary) CHO technology is used to create monoclonalantibodies. Hybrid cell ensures antibody production continuously in dividing cells. Increasing use of these hybrid cells for cell line development is driving the cell line development market growth for this segment. In addition, companies are also positioning themselves competitively in the cell line development landscape. For instance, in February 2017, GE Healthcare (US) entered a three-year collaboration with the Austrian Centre of Industrial Biotechnology to identify new techniques for optimizing CHO cell-line performance. The collaboration’s initial emphasis is on CHO cell-line growth and expression.
Continuous cell culture is part of a trend in bioprocessing toward highly productive, streamlined, and interconnected unit operations.Increasing adoption of these types of cell lines in biopharmaceutical industries is driving the cell line development market growth for this segment.
The recombinant protein production used in mammalian cells and insect cell lines is called a recombinant cell line. The recombinant cell line segment held the largest share in 2020, owing to factors such as rising demand for recombinant proteins and the adoption of recombinant cell lines of biotherapeutics.Moreover, increasing demand for toxicity testing is also contributing to the growth of this cell line development market segment.
Based on the equipment, of global cell line development market is segmented into incubators, centrifuges, bioreactors, storage equipment, microscopes, and others. These equipment are majorly being used for the large-scale development of cell lines for various applications.
Based on the media and reagents segment is further divided into serum, media, and reagents.Media and reagents segment held the largest share in the year 2020. Increasing use of these consumables for cell line development is fueling the cell line development market growth of this segment.An increasing number of laboratory setups for biologics production and R&D activities also contribute to cell line development market growth.
Mammalian cells are expected to hold the major share in 2021. The key factor attributing to the growth of the cell line development market is the rising adoption of a mammalian source for the production ofmonoclonal antibodies (mAbs). The necessity for expressing complex proteins similar to human beings is alsoexpected to boost the adoption of this productin the coming years.
Based on the source of global cell line development, the non-mammalian segmented is segmented into insects and amphibians. Protein therapeutics mAbs peptides and recombinant proteins represent the largest group of new products in development by the biopharmaceutical industry. These protein therapeutics are derived from non-mammalian sources for cell line development; this aids in boosting the cell line development market growth of this segment.
Cell line development is a major step for assessing the efficiency of drug discovery, toxicity, and in vitro testing. The advantages of cell line development in this process include reduced time, effort, and cost, which minimizes the chance of research drugs failing at the clinical trial stage. This is attributing to the cell line development market growth of this segment.
The bioproduction segment held the largest share in 2020 due to factors such as the wideavailability of cell lines for bioproduction, the increasing number of antibiotics, and vaccine production. These factors are contributing to the cell line development market growth of this segment.
Tissue engineering is the construction of bioartificial tissues in vitro as well as within vivo methods of cell growth and function via implantation of suitable cells isolated from donor tissue and biocompatible scaffold materials. Increasing adoption of the cell line for tissue engineering is boosting the cell line development market growth of this segment.
Others include toxicity testing,regenerative medicine, etc.The increasing use of cell lines in these applications is driving the cell line development market growth of this segment.
The market in North America accounted for the largest share in 2020 due to the presence of constant technological developments followed by new discoveries triggering the adoption of novel procedures for bioproduction. The presence of well-established players involved in new launches and collaborationsfor cell line development, such as Thermo Fisher Scientific Inc. (US), American Type Culture Collection (ATCC), and Sigma-Aldrich Corporation (US), which provide high-quality biologics services, is contributing to the cell line development market growth. For instance, in October 2019, ATCC (US)launcheda portfolio of exosomes (i.e., extracellular vesicles) derived from human cells to serve as reference materials or standards for a variety of research applications. The first two exosomes available to researchers are derived from the A549 non-small cell lung cancer (NSCLC) cell line and hTERT-immortalized mesenchymal stem cells.
The European cell line development market is driven bysupportive government initiatives for cell line development procedures and growing awareness pertaining to monoclonal antibodyapplications in cancer treatment.
The Asia-Pacific is expected to witness rapid growth in the global cell line development market. Asia-Pacific regional market is anticipated to witness lucrative growth due to increasing healthcare expenditure by government and private sector companies. For instance, in India, the Department of Science and Technology (DST), Department of Biotechnology (DBT), Department of Scientific & Industrial Research (DSIR) are regulating the production and guidelines for biotechnology products. These organizations provide guidelines related to manufacturing or transferring of technology and generating manpower for productionraising funds.
Rest of the World:
The cell line development market in the rest of the world is driven bytechnological development in the biotechnology industry, manufacturing, screening technologies, and assays. The increasing number of government initiatives for improving the healthcare sector is another factor boosting the growth of the cell line development market in this region.
The cell line development market is profitable, both for existing players as well as new entrants. A substantial level of competitive rivalry is witnessed among the market players. Based on the analysis, that market players have adopted different strategies and innovative research and development techniques to expand their business and secure their position in the global cell line development market. For instance, in 2018, Denali Therapeutics (US) entered into a partnership with Lonza (Switzerland) to develop and produce biologic medicines using the latter’s cell line development technology GS Xceed.The prominent players are involved in strategic agreements, product launches, and joint ventures to sustain their market positions.
The study covers the existing short-term and long-term market effect, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers major regions in North America, Europe, Asia-Pacific, and therest of the world. The report analyzes market drivers, restraints, opportunities, challenges, Porter’s Five Forces, Value Chain, and impact of COVID-19 on the market.
Scope of the Report
The scope of the global cell line development market study includes a market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on type, product, source, application, and region.
Key Market Opportunities
Rising adoption of mammalian cells for monoclonal antibody production
Key Market Drivers
Global Cell Line Development, by Type
Global Cell Line Development, by Product
Global Cell Line Development, by Source
Global Cell Line Development, by Application
Global Cell Line Development, by Region
|Market Size||2027: USD 10,700 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Product, Source, Application|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||American Type Culture Collection (ATCC) (US), Lonza Group AG (Switzerland), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), Sigma-Aldrich Corporation (US), Selexis SA (Switzerland), Promega Corporation (US), Corning Inc. (US), WuXiAppTec Inc. (China), Sartorious AG (Germany)|
|Key Market Opportunities||Rising adoption of mammalian source for monoclonalantibody production|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Cell line development (CLD) is a process that is being used for a variety of research and drug development and production application such as drug target identification and biologic drug production.
cell line development market is expected to cross USD 10,700 million by 2027
cell line development market is expected to exhibit a strong 12.5% CAGR by 2027
The rise in research activities in cell line development as a crucial step triggers the demand for cell line development, Companies are involved in R&D and are collaborating with other companies, Introduction of advanced technologies *Rise in vaccine productionby using cell line development process.
The market in North America accounted for the largest share in 2020 due to the presence of constant technological developments followed by new discoveries triggering the adoption of novel procedures for bioproduction.
Some of the key players in the global cell line development marketareAmerican Type Culture Collection (ATCC) (U.S.), Lonza Group AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), GE Healthcare (U.S.), Sigma-Aldrich Corporation (U.S.), Selexis SA (Switzerland), Promega Corporation (US), Corning, Inc. (U.S.), WuXiAppTec, Inc. (China), and Sartorious AG (Germany).
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.